NCT03417765View on ClinicalTrials.gov

Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 1, 2018

Primary Completion Date

March 31, 2019

Study Completion Date

March 31, 2019

Conditions
Lymphoma, Non-Hodgkin's, AdultLymphoma, Hodgkin's, Adult
Interventions
DRUG

FE 203799

GLP-2 analogue, once weekly, subcutaneous administration

Sponsors
All Listed Sponsors
collaborator

VectivBio AG

INDUSTRY

lead

GlyPharma Therapeutics

INDUSTRY